ProfileGDS5678 / 1434520_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 34% 34% 34% 60% 39% 36% 45% 49% 65% 39% 37% 44% 35% 44% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8177134
GSM967853U87-EV human glioblastoma xenograft - Control 22.7787334
GSM967854U87-EV human glioblastoma xenograft - Control 32.7820134
GSM967855U87-EV human glioblastoma xenograft - Control 43.5349360
GSM967856U87-EV human glioblastoma xenograft - Control 52.8403239
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8905536
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1094945
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1653849
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.8752965
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8705839
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8329337
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9901644
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8111935
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0087344